UPS To Acquire Marken, A Leader In Global Clinical Supply Chain Solutions
November 07 2016 - 9:25AM
Transaction Highlights
- UPS announces agreement to acquire privately held Marken
- Underscores UPS commitment to healthcare and pharma
industries
- Positions UPS as a leading provider in clinical trials supply
chain solutions
- Marken to operate as a wholly owned subsidiary of UPS
- Marken to access UPS integrated global network for further
efficiency
UPS (NYSE:UPS) has entered into a definitive purchase agreement
to acquire Marken, a global provider of supply chain solutions to
the life sciences industry. The transaction, which provides UPS
with growth opportunities across the life sciences customer base,
is expected to close by Dec. 31, subject to customary conditions
and regulatory approvals. Terms of the acquisition were not
disclosed.
Clinical trials require strict regulatory compliance,
streamlined logistics services and global reach. Marken operates a
global network of clinical supply chain services to meet the
increasingly complex demands of its clients. The acquisition of
Marken follows multiple UPS acquisitions that have expanded the
company’s healthcare logistics services portfolio.
“Healthcare logistics is a strategic market for UPS. Our
acquisition of Marken strengthens our portfolio and demonstrates
our commitment to customers,” said Teresa Finley, UPS Chief
Marketing and Business Services Officer.
“We plan to offer new solutions to our customers and generate
further growth opportunities for UPS.”
“We are excited to join the UPS organization,” said Wes Wheeler,
Marken’s Chief Executive Officer. “UPS’s capabilities, particularly
in mature markets, will provide many opportunities for us to
enhance our service offerings in clinical trials logistics.
With UPS, we will improve our efficiency, while continuing to
provide our clients with the high-touch, personalized services that
they have come to expect from us.”
Wheeler will continue to lead the Marken business, which will
operate as a wholly-owned subsidiary of UPS.
Pharmaceutical companies, clinical research organizations and
contract manufacturers rely on Marken for collection and
transportation of clinical trial material and investigational
medicinal products to 49,000 clinical trial sites, as well as the
shipment of biological samples from these sites to central
laboratories. These shipments are time- and temperature-sensitive,
and their rapid, on-spec delivery is a key factor in the treatment
of patients and the success of the clinical trial. The company has
more than 650 employees with an asset-light operating structure and
44 locations worldwide, including 10 depots that are compliant with
Good Manufacturing Practices (GMP). Marken provides high-touch
service to pharmaceutical companies, manufacturers and contract
research organizations engaged in all phases of the clinical trials
process.
“UPS is focused on the logistics complexity of clinical trials,
and the acquisition fits well into our long-term growth plans in
the biopharma segment,” Finley said. “Marken’s significant industry
expertise and flexible network, combined with UPS’s vast integrated
global air and ground networks, will provide the life sciences
industry with an attractive portfolio of global logistics
options.”
UPS offers a broad array of specialized services for healthcare
and life science companies. In July, UPS announced expanded
logistics capabilities for clinical trials. The company’s network
includes temperature-sensitive storage and transportation (from
ambient and controlled-room temperature, to frozen and cryogenics),
24-hour monitoring and security.
UPS now has more than 100 healthcare-dedicated facilities with
60 GMP-compliant locations strategically positioned within global
markets. Shippers have the ability to customize solutions from the
UPS Temperature True™, UPS Proactive Response™, UPS WorldShip™, UPS
Quantum View™ and other portfolios that leverage expertise in
packaging, labeling, monitoring and storage capabilities.
J.P. Morgan served as the financial advisor to UPS. UBS
Investment Bank acted as the financial advisor to Marken.
About UPS
UPS (NYSE: UPS) is a global leader in logistics, offering a
broad range of solutions including transporting packages and
freight; facilitating international trade, and deploying advanced
technology to more efficiently manage the world of business.
Headquartered in Atlanta, UPS serves more than 220 countries and
territories worldwide. The company can be found on the web
at ups.com® and its corporate blog can be found
at longitudes.ups.com. To get UPS news direct,
visit pressroom.ups.com/RSS or follow
@UPS_News.
About Marken
Marken is the only patient-centric supply chain organization
100% dedicated to the pharmaceutical and life sciences industries.
Marken maintains the leading position for Direct to Patient
services and biological sample shipments and offers a
state-of-the-art GMP-compliant depot network and logistic hubs in
44 locations worldwide for clinical trial material storage and
distribution. Marken’s more than 650 staff members manage 50,000
drug and biological shipments every month at all temperature ranges
in more than 150 countries. Additional services such as
biological kit production, ancillary material sourcing, storage and
distribution, shipment lane verification and qualifications, as
well as GDP, regulatory and compliance consultancy add to Marken’s
unique position in the pharma and logistics industry.
Kyle Peterson, UPS
(404) 828-4626
kylepeterson@ups.com
David Graves, UPS
(404) 828-6798
davidgraves@ups.com
Christine Noble, Marken
(919) 474-6890
Christine.Noble@marken.com
United Parcel Service (NYSE:UPS)
Historical Stock Chart
From Mar 2024 to Apr 2024
United Parcel Service (NYSE:UPS)
Historical Stock Chart
From Apr 2023 to Apr 2024